Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
699 people get APRI articles and Market Currents by email alert.
Get email alerts on APRI »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
GlobeNewswire (May 10, 2013)
-
-
GlobeNewswire (May 7, 2013)
-
-
GlobeNewswire (Apr 18, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
-
GlobeNewswire (Mar 18, 2013)
-
GlobeNewswire (Mar 18, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 13, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
GlobeNewswire (Feb 6, 2013)
-
-
-
GlobeNewswire (Jan 3, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
Apricus Jumps in Anticipation of Quarterly EarningsVFC's Stock House • Wed, May 11, 2011
-
Contrasting Opinions on Apricus Are to Be ExpectedVFC's Stock House • Thu, Apr 28, 2011
-
-
-
-
-
-
-
GlobeNewswire (May 10, 2013)
-
GlobeNewswire (May 7, 2013)
-
GlobeNewswire (Apr 18, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Mar 18, 2013)
-
GlobeNewswire (Mar 18, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 13, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
GlobeNewswire (Feb 6, 2013)
-
GlobeNewswire (Jan 3, 2013)
-
GlobeNewswire (Nov 21, 2012)
-
GlobeNewswire (Nov 8, 2012)
-
GlobeNewswire (Nov 7, 2012)
-
GlobeNewswire (Nov 6, 2012)
-
GlobeNewswire (Oct 18, 2012)
-
GlobeNewswire (Oct 1, 2012)
-
GlobeNewswire (Sep 25, 2012)
APRI vs. ETF Alternatives
Company Description
Currently, there's no company description for APRI.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 15, 2:29 PM Apricus Biosciences (APRI +15%) ramps higher today after its board of directors votes to terminate the company's shareholder rights agreement. With the poison pill out of the way, investors appear to be placing bets on a future takeout of the company. Comment! [Healthcare, On the Move]
- Tuesday, April 2, 12:16 PM Apricus Biosciences (APRI +2%) moves up today after reporting the sale of some non-core assets: Totect, a marketed, injectable treatment for anthracycline extravasation, and NitroMist, an FDA-approved nitrate vasodilator that treats angina pectoris. Financial details of the sale were not disclosed Comment! [Healthcare, On the Move]
- Monday, April 1, 4:50 PM Apricus Biosciences (APRI) moves ahead with its planned divestiture of non-core assets as it sells its extravasation injection Totect to Biocodex and its nitrate vasodilator NitroMist to Mist Pharmaceuticals. The company says it sold the products "in line with their initial up-front purchase price." Comment! [Healthcare]
- Monday, March 18, 12:31 PM Apricus Biosciences (APRI -4%) slips today after the company gives an update on corporate activities and announces it's appointed Richard Pascoe, a 20-year veteran in the biopharmaceutical industry, as its new CEO as the company begins development and marketing of Vitaros and Femprox. Comment! [Healthcare, On the Move]
-
Tuesday, February 12, 12:45 PM
Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%. Comment! [On the Move] - Wednesday, November 7, 2012, 12:45 PM Midday top 10 gainers: CALI +89%. SRT +22%. VHC +21%. AMRS +20%. HDY +19%. PKT +16%. FCAL +14%. CNTF +12%. MKTG +10%. SGI +10%. Midday top 10 Losers: QLTY -34%. PLXS -28%. STEC -23%. JRCC -21%. PQ -18%. APRI -18%. FRM -17%. RBCN -17%. PHMD -17%. THQI -17%. Comment!
- Tuesday, November 6, 2012, 5:56 PM Apricus Biosciences (APRI) says that its director, president and CEO, Bassam Damaj, Ph.D., has resigned effective immediately, and that Steve Martin, senior vice president and CFO, has been appointed interim CEO. The company also announced that its board has retained an executive recruiting firm to assist in identifying a permanent CEO with pharmaceutical industry experience. Shares -2.3% AH. 1 Comment [Healthcare, On the Move]
- Monday, October 1, 2012, 8:00 AM Shares of Apricus Biosciences (APRI) soar 11.1% premarket after the company announces that it will file a new drug submission in Canada for MycoVa in Q4 of 2013. In advanced testing, MycoVa has shown an ability to kill nail fungus and improve the appearance of nails. Comment! [On the Move, Healthcare]
- Thursday, September 13, 2012, 9:22 AM Apricus Biosciences (APRI) +12.5% premarket after announcing it has licensed Takeda Pharmaceuticals (TKPHF.PK, TKPYY.PK) to market Vitaros, its erectile dysfunction drug, in the U.K. Takeda will pay APRI an undisclosed upfront payment and milestone payments of up to 35M euros. 1 Comment [Healthcare, On the Move]
-
Thursday, September 13, 2012, 9:10 AM
Premarket gainers: EQIX +14%. VICL +13%. APRI +13%. LRN +10%. PLL +7%. CTIC +5%.
Losers: CCRT -29%. PSTI -17%. FMER -7%. USG -6%. HK -5%. 1 Comment [On the Move] - Monday, July 16, 2012, 5:38 PM Apricus Biosciences (APRI) files a 3.7M share registration statement. Stock -5.6% AH. 1 Comment [Healthcare, On the Move]
- Wednesday, February 15, 2012, 1:01 PM Shares of Apricus Biosciences (APRI +4.4%) kick up a gain after the firm announces that its NexMed subsidiary has signed a collaboration agreement with a division of Novartis (NVS +0.1%) to market Vitarose in Germany. Comment! [On the Move, Healthcare, Global & FX]
- Monday, January 9, 2012, 3:22 PM Apricus Bioscience (APRI +4.8%) trades higher after Abbott Laboratories (ABT) signs an exclusive licensing and marketing agreement with the company to sell Vitaros, Apricus' treatment for erectile dysfunction, in Canada. Comment! [Healthcare, On the Move]
- Friday, December 30, 2011, 5:37 PM Apricus Biosciences (APRI) files $100M mixed securities shelf registration, representing a dilution of nearly 10% to its current market cap. Shares -7% AH. Comment! [Healthcare]
- Thursday, December 8, 2011, 3:40 PM Apricus Bioscience (APRI +1.2%) says the Japanese Patent Office has issued an official decision to allow the company's application covering compositions and methods related to Crystalline Salts and its NexACT permeation enhancer technology used in topical drug delivery. Comment! [Healthcare, Global & FX, On the Move]
- Friday, September 2, 2011, 11:12 AM Apricus Biosciences (APRI -5%) trades lower this morning after admitting it made misleading statements by citing FDA "approval" for three of its new OTC drugs when it should have said they were "compliant." Comment! [Healthcare, On the Move]
-
Dustin Moore
$APRI starting run up to EU decision set in a few weeks? I'll explain why approval is likely soon... - View all 0 replies
-
rvanlith
Looks like Vitaros will finally be sold in Canada now. $APRI , Here we go. http://bit.ly/UBRkyd - View all 0 replies
-
Dustin Moore
$APRI Vitaros presentation shows saftey profile/clinically sustained improvement for patients with ED http://bit.ly/Un1gI3 - View all 0 replies
-
Justin M. Hall
10/18/12 2:36P ET: { Results Update } We decided to exit APRI today with a nominal gain. http://bit.ly/t7mrwo - View all 2 replies
-
Justin M. Hall: Near-term, APRI is likely to head south, possibly as low as $2.25 or so. We may revisit this stock again at lower levels.
-
bhowell350: looks like you made a good call.. Is this now the time to reenter? Abbot is now saying a first half 2013 intro for Vitaros in Canada
-
Dustin Moore
$APRI SEC filing suggests positive guidance re $WCRX Vitaros ED drug http://bit.ly/SKQqhl - View all 0 replies
-
Dustin Moore
Ascendiant Capital issues strong-buy for Apricus $APRI 3.38 (+8.33%) - Price Tartget $8 http://bit.ly/N2Y5lC - View all 0 replies
-
The Scientist
Waiting for huge catalyst on APRI. Should be any day that Europe makes decision on Vitaros. - View all 1 replies
-
Roy Manning III: It was announced that Vitaros European approval would be delayed at least 8 months. Check the quarterly report and conference call.
-
Todd Theman
wondering when fortunes will turn around for APRI...need to see some sales numbers, but anticipating a nice return from these levels - View all 0 replies
-
- View all 1 replies
-
Perkins Cove: "European Patent Office allows patent application". (Briefing.com)
-
The Scientist
Still waiting for a response from AF from The Street on the licensing deals by APRI with ABT and NVS. Shows the value of NexACT technology - View all 1 replies
-
The Scientist: Huge multi-national biotechs do not do licensing deals with microcap biotech's unless they felt the technology is novel.
LATEST REPLIES
-
Justin M. Hall
10/18/12 2:36P ET: { Results Update } We decided to exit APRI today with a nominal gain. http://bit.ly/t7mrwo - View all 2 replies
-
Justin M. Hall: Near-term, APRI is likely to head south, possibly as low as $2.25 or so. We may revisit this stock again at lower levels.
-
bhowell350: looks like you made a good call.. Is this now the time to reenter? Abbot is now saying a first half 2013 intro for Vitaros in Canada
-
The Scientist
Waiting for huge catalyst on APRI. Should be any day that Europe makes decision on Vitaros. - View all 1 replies
-
Roy Manning III: It was announced that Vitaros European approval would be delayed at least 8 months. Check the quarterly report and conference call.
-
- View all 1 replies
-
Perkins Cove: "European Patent Office allows patent application". (Briefing.com)
-
The Scientist
Still waiting for a response from AF from The Street on the licensing deals by APRI with ABT and NVS. Shows the value of NexACT technology - View all 1 replies
-
The Scientist: Huge multi-national biotechs do not do licensing deals with microcap biotech's unless they felt the technology is novel.